Bioavailability of Dabigatran With or Without Clarithromycin in Healthy Volunteers

NCT02171585 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-06-24

No results posted yet for this study

Summary
Conditions
Interventions
Sponsors
Investigators
Design
Eligibility
Timeline
Countries
Locations
Related
Entities

Summary

To investigate whether and to what extent the reported potent P-gp inhibitor clarithromycin affects pharmacokinetic parameters (area under the curve (AUC) and maximal concentration (Cmax)) of dabigatran.

Conditions

Healthy

Interventions

DRUG: Dabigatran etexilate
DRUG: Clarithromycin

Sponsors & Collaborators

Boehringer Ingelheim
lead INDUSTRY

Study Design

Allocation: NON_RANDOMIZED
Purpose: TREATMENT
Masking: NONE
Model: CROSSOVER

Eligibility

Min Age: 18 Years
Max Age: 50 Years
Sex: ALL
Healthy Volunteers: Yes

Timeline & Regulatory

Start: 2008-06-30
Primary Completion: 2008-08-31

More Related Trials

Entities

Companies

Boehringer Ingelheim

Summary

Conditions

Interventions

Sponsors & Collaborators

Study Design

Eligibility

Timeline & Regulatory

Related Clinical Trials

Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy Volunteers

Relative Bioavailability of Dabigatran and Digoxin in Healthy Male and Female Volunteers

Bioavailability of Dabigatran and Amiodarone After Multiple Oral Administrations of Dabigatran Etexilate With or Without Amiodarone as Single Dose in Healthy Male and Female Volunteers

Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers

Bioavailability of Different Applications of Dabigatran in Healthy Volunteers

More Related Trials

Entities